This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

St. Jude Medical Reports Fourth Quarter And Full-Year 2012 Results

Fourth quarter pacemaker sales were $260 million, an 11 percent decrease compared to the fourth quarter of 2011. Total pacemaker sales for 2012 were $1.111 billion, down 8 percent compared to pacemaker sales in 2011. On a constant currency basis, total pacemaker sales declined 6 percent from the prior year.

Atrial Fibrillation (AF)

AF product sales for the fourth quarter totaled $239 million, a 10 percent increase over the fourth quarter of 2011. On a constant currency basis, AF product sales increased 11 percent in the fourth quarter of 2012. For the full-year 2012, AF product sales were $898 million, an increase of 9 percent over the prior year. On a constant currency basis, AF product sales increased 12 percent in 2012.

Cardiovascular

Total cardiovascular sales, which primarily include vascular and structural heart products, were $338 million for the fourth quarter of 2012, approximately equal to the fourth quarter of 2011. Total cardiovascular product sales for 2012 were $1.328 billion, down 1 percent from 2011, including a $36 million decrease due to unfavorable foreign currency translations. On a constant currency basis, cardiovascular product sales increased 2 percent in 2012.

Total structural heart product sales for the fourth quarter of 2012 were $152 million, approximately equal compared with the fourth quarter of 2011. Total structural heart product sales for 2012 were $612 million, an increase of 3 percent compared to 2011 or 6 percent on a currency neutral basis.

Sales of vascular products in the fourth quarter of 2012 were $186 million, a 2 percent decrease from the fourth quarter of 2011. Total vascular product sales for 2012 were $716 million, down about 3 percent from 2011 or down 1 percent on a constant currency basis.

Neuromodulation

St. Jude Medical sales of neuromodulation products were $113 million in the fourth quarter of 2012, down 7 percent from the prior year. Total neuromodulation product sales for 2012 were $423 million, up 1 percent over the prior year including a $7 million decrease due to unfavorable currency translations.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs